12 June 2024 : Database Analysis
Comparative Cardiovascular Risks of Febuxostat and Allopurinol in Patients with Diabetes Mellitus and Chronic Kidney Disease
Hsin Hsiang Huang1DE, Yun-Yi Chen23BCD, Yu-Wei Fang14ADG, Hung-Hsiang Liou5AD, Jing-Tong Wang1B, Ming-Hsein Tsai14ADE*DOI: 10.12659/MSM.944314
Med Sci Monit 2024; 30:e944314
Table 4 Clinical outcomes in patients with diabetes mellitus and chronic kidney disease.
| Clinical outcomes | Before matching | |||||
|---|---|---|---|---|---|---|
| Febuxostat users (n=2,997) | Allopurinol users (n=12,901) | Febuxostat users vs allopurinol users | ||||
| Events | Incidence rate (1000 PYs) | Events | Incidence rate (1000 PYs) | HR (95% CI) | p value | |
| All-cause hospitalization | 2226 | 307.4 | 9510 | 219.8 | 1.41 (1.34–1.48) | <0.001 |
| Hospitalization for heart failure | 666 | 53.2 | 2293 | 30.6 | 1.94 (1.76–2.13) | <0.001 |
| Hospitalization for cardiovascular intervention | 493 | 38.1 | 1978 | 26.1 | 1.59 (1.43–1.76) | <0.001 |
| * | ||||||
| All-cause hospitalization | 2254 | 241.3 | 1.33 (1.24–1.41) | <0.001 | 1.33 (1.25–1.42) | <0.001 |
| Hospitalization for heart failure | 612 | 36.9 | 1.60 (1.42–1.81) | <0.001 | 1.62 (1.43–1.83) | <0.001 |
| Hospitalization for cardiovascular intervention | 480 | 28.2 | 1.52 (1.32–1.74) | <0.001 | 1.51 (1.32–1.74) | <0.001 |
| * The multivariate analysis encompasses hypertension, ischemic heart disease, congestive heart failure, atrial fibrillation, peripheral vascular disease, stroke, hyperlipidemia, calculus of kidney, cirrhosis, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers, calcium channel blockers, antithrombotic agents, non-steroidal anti-inflammatory drugs, fenofibrate, statins, and diuretics. HR – hazard ratio; PYs – person years, CI – confidence interval. | ||||||